Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 7.4 vs MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Provides essential electrolytes (calcium, magnesium, potassium, sodium, acetate, chloride) to maintain or restore electrolyte balance, acid-base equilibrium, and osmotic pressure in extracellular fluid. Calcium and magnesium are critical for neuromuscular function and enzymatic reactions. Acetate is metabolized to bicarbonate in the liver and peripheral tissues, serving as an alkalinizing agent to correct acidosis.
Administration of electrolytes to correct deficiencies or maintain homeostasis; no pharmacological target.
Source of electrolytes and water for parenteral maintenance or replacement therapy when oral intake is inadequate,Correction of electrolyte imbalances,Alkalinizing agent for metabolic acidosis (via acetate)
Source of electrolytes for intravenous administration when oral intake is not possible or sufficient,Maintenance of fluid and electrolyte balance
Intravenous infusion; dose determined by individual electrolyte requirements and fluid status. Typical adult dose: 500-1000 m L as a continuous infusion at a rate of 100-200 m L/hour, not to exceed 3 L/day.
Intravenous administration of 500-1000 m L at a rate of up to 1 L/hour, adjusted based on electrolyte status and fluid balance.
Not applicable as components are endogenous; exogenous electrolytes have functional half-lives of minutes to hours depending on compartment equilibration.
The half-life is not applicable as a single value because electrolytes are homeostatically regulated. For potassium, the terminal elimination half-life is approximately 12 hours in healthy individuals, but it is highly dependent on renal function and serum levels.
Acetate is metabolized to bicarbonate in the liver and peripheral tissues via acetyl-Co A and the Krebs cycle. Electrolytes (calcium, magnesium, potassium, sodium, chloride) are not metabolized and are excreted primarily renally, with minor losses via feces and sweat.
Electrolytes are not metabolized; excreted primarily by kidneys.
Renal: >95% as infused electrolytes via glomerular filtration and tubular handling. Biliary/fecal: <5% in normal renal function.
Electrolytes are primarily eliminated via renal excretion ( >95% ). Biliary/fecal elimination is negligible (<5%).
Negligible (<5%); electrolytes are free ions in plasma.
Electrolytes are minimally protein-bound: Sodium <5%, Potassium <5%, Calcium ~40-50% (bound to albumin), Magnesium ~30% (bound to albumin), Chloride <5%, Bicarbonate <5%.
Varies by ion: Na+ ~0.5 L/kg (extracellular), K+ ~4 L/kg (intracellular), Cl- ~0.3 L/kg. Overall composite Vd ~0.2-0.5 L/kg.
Sodium: 0.6-0.7 L/kg (primarily extracellular); Potassium: 4-5 L/kg (mainly intracellular); Calcium: 0.3-0.5 L/kg; Magnesium: 0.5-0.7 L/kg. Reflects distribution into body fluid compartments.
Intravenous: 100% (complete).
Intravenous: 100%. Not administered via other routes; oral supplementation is available separately.
GFR 30-50 m L/min: Reduce infusion rate by 50%; monitor serum electrolytes closely. GFR <30 m L/min: Avoid use due to risk of hyperkalemia and hyperphosphatemia; use alternative electrolyte preparation.
Contraindicated in anuria or severe renal impairment (GFR <30 m L/min) due to risk of electrolyte overload. For GFR 30-60 m L/min, reduce infusion rate and monitor electrolytes closely.
Child-Pugh Class C: Avoid use due to risk of fluid overload and electrolyte imbalances; consider alternative with lower volume and adjusted electrolyte content.
No specific Child-Pugh based dose adjustments; however, monitor for electrolyte disturbances, particularly in severe hepatic impairment (Child-Pugh C) due to altered metabolism.
Weight-based: 20-40 m L/kg/day as continuous infusion; adjust rate based on serum electrolytes and fluid balance. Maximum infusion rate: 100 m L/hour.
Intravenous dosing based on weight: 20-30 m L/kg/day, adjusted according to serum electrolyte levels and clinical condition. Infuse at a rate not exceeding 5 m L/kg/hour.
Use with caution due to age-related decline in renal function. Start at lower infusion rate (50-100 m L/hour) and monitor electrolytes, fluid balance, and cardiac function closely.
Use with caution due to age-related decline in renal function; start with lower infusion rates (e.g., 250-500 m L over 2-4 hours) and monitor renal function and electrolytes frequently.
None
None.
Risk of fluid and/or solute overload leading to dilution of serum electrolyte concentrations, overhydration, congested states, or pulmonary edema,Risk of aluminum toxicity in patients with impaired renal function due to aluminum content of the injection,Avoid rapid administration of calcium-containing solutions to prevent hypercalcemia and cardiac arrhythmias,Monitor serum electrolytes, renal function, and acid-base balance during therapy,Use with caution in patients with heart failure, renal impairment, or conditions predisposing to hyperkalemia (e.g., burns, severe trauma) due to potassium content,Do not use if solution is discolored or contains precipitate; use administration set with filter
Monitor serum electrolytes, fluid balance, and acid-base status,Use with caution in patients with renal impairment, heart failure, or conditions predisposing to fluid/electrolyte disturbances,Risk of hyperkalemia with potassium-containing solutions,Risk of hypercalcemia if calcium is present
Hyperkalemia,Hypercalcemia,Hypermagnesemia,Hypernatremia,Patients with severe renal impairment (oliguria, anuria) unless dialysis is used,Patients with metabolic alkalosis,Concurrent use of digoxin (increased risk of arrhythmias due to calcium),Do not administer to patients with known hypersensitivity to any component
Hyperkalemia, hypercalcemia, hypernatremia, or hypermagnesemia,Severe renal impairment with oliguria/anuria,Addison's disease (unrelated to sodium source),Concurrent use of potassium-sparing diuretics (if contains potassium)
No specific food interactions. However, electrolyte balance may be affected by dietary intake; patients should maintain a balanced diet as advised by their clinician.
No specific food interactions known. However, dietary intake of electrolytes may need adjustment based on serum levels and underlying conditions. Patients on this IV therapy should follow their healthcare provider's dietary recommendations regarding salt and fluid intake.
No studies in pregnant women; animal reproduction studies not conducted. Contains electrolytes at physiologic concentrations: sodium 140 m Eq/L, potassium 5 m Eq/L, calcium 2.5 m Eq/L, magnesium 1.5 m Eq/L, chloride 98 m Eq/L, acetate 27 m Eq/L, gluconate 23 m Eq/L. No known teratogenic effects at therapeutic doses. Risk of electrolyte imbalance if administered inappropriately.
No teratogenic risk; electrolytes are physiologic substances and essential for normal fetal development. No increased risk of congenital anomalies at therapeutic doses.
Excreted into human milk; electrolytes equilibrate with maternal serum. M/P ratio not established. Compatible with breastfeeding when used at physiologic doses; monitor infant for electrolyte disturbances if maternal serum levels are abnormal.
Generally safe; electrolytes are naturally present in breast milk and transfer into milk in proportion to maternal plasma levels. M/P ratio not established but considered 1:1. No adverse effects expected in breastfed infants.
No standard dose adjustments recommended. Pregnancy-induced plasma volume expansion and increased glomerular filtration may require individualized dosing based on serial electrolyte measurements, especially in preeclampsia or renal impairment.
No routine dose adjustment needed; pregnancy may alter electrolyte requirements (e.g., increased volume of distribution, renal changes). Dose should be individualized based on serum electrolyte monitoring, but no fixed adjustment recommended.
Contains sodium chloride, potassium chloride, magnesium chloride, and sodium acetate in a p H 7.4 buffer. Used as a source of water and electrolytes for maintenance or replacement therapy. Monitor serum electrolytes, particularly potassium and magnesium, in renal impairment. Do not administer unless solution is clear and container undamaged. Use with caution in patients with heart failure, renal failure, or hyperkalemia.
Multiple Electrolytes Injection Type 1 USP p H 5.5 is a sterile, nonpyrogenic solution of electrolytes in water for injection, containing sodium chloride, potassium chloride, calcium chloride, and magnesium chloride. It is used for fluid and electrolyte replacement. Monitor serum electrolytes, renal function, and cardiac status during administration. Avoid in patients with hyperkalemia, hypercalcemia, hypermagnesemia, or severe renal impairment. Use with caution in heart failure or edema. Check compatibility with other IV fluids and medications.
This solution is given intravenously to replace fluids and electrolytes.,Inform your healthcare provider if you have kidney disease, heart disease, or high potassium levels.,Report any signs of fluid overload such as shortness of breath, swelling in the ankles or feet.,Do not suddenly stop or change the infusion rate without consulting your doctor.,Seek immediate medical attention if you experience chest pain, irregular heartbeat, or muscle weakness.
This injection is given to replace fluids and electrolytes in your body.,You may need regular blood tests to check your electrolyte levels.,Tell your healthcare provider if you have kidney problems, heart disease, or are on a salt-restricted diet.,Report any signs of too much fluid in your body, such as swelling, shortness of breath, or rapid weight gain.,This medication is only given by a healthcare professional.
No interactions on record
No interactions on record
Common clinical questions about MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 7.4 vs MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5, answered by our medical review team.
MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 7.4 is a Electrolyte Replacement Solution that works by Provides essential electrolytes (calcium, magnesium, potassium, sodium, acetate, chloride) to maintain or restore electrolyte balance, acid-base equilibrium, and osmotic pressure in extracellular fluid. Calcium and magnesium are critical for neuromuscular function and enzymatic reactions. Acetate is metabolized to bicarbonate in the liver and peripheral tissues, serving as an alkalinizing agent to correct acidosis.. MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5 is a Electrolyte Replacement Solution that works by Administration of electrolytes to correct deficiencies or maintain homeostasis; no pharmacological target.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 7.4 and MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5 depend on the specific clinical indication. These are both Electrolyte Replacement Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 7.4 is: Intravenous infusion; dose determined by individual electrolyte requirements and fluid status. Typical adult dose: 500-1000 m L as a continuous infusion at a rate of 100-200 m L/hour, not to exceed 3 L/day.. The standard adult dose of MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5 is: Intravenous administration of 500-1000 m L at a rate of up to 1 L/hour, adjusted based on electrolyte status and fluid balance.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 7.4 and MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 7.4 is classified as Category C. No studies in pregnant women; animal reproduction studies not conducted. Contains electrolytes at physiologic concentrations: sodium 140 mEq/L, potassium 5 mEq/L, calcium 2.5 mEq/L. MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5 is classified as Category C. No teratogenic risk; electrolytes are physiologic substances and essential for normal fetal development. No increased risk of congenital anomalies at therapeutic doses.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.